In our coverage of biotechnology this week, analyst Liisa Bayko talks about her concerns in the Biotechnology Sector:
TWST: Are there any names that worry you?
Ms. Bayko: I think Dendreon is a little bit of a worry because it’s so volatile.It’s trading up now, and I have a sell rating on it. They are in the prostate cancer space. Their ongoing trial is called IMPACT, and we are going to have the data from that the middle of the next year. I worry if that’s going to be positive. They are putting so much into making that positive, that’s my concern. If it’s not positive, then what?
For our full coverage of the Biotech sector, featuring interviews with CEOs from 20 different companies, click here.
Two Doctors’ Prescription for Ailing Biotech
February 25, 2008
Biotech Pic: Gilead Sciences
February 26, 2008
Biotech Terminates CEO and Others
September 29, 2009
Less Volatility in Biotech as Capital Markets Unwind
April 07, 2010
With Health Care Reform Settled, Flurry of M&A Activity in Biotech
April 15, 2010
